about
Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulationmiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cellsStrong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patientsNoninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging systemClinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype.SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating Akt/FoxO3a signaling.DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapyPaclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy.Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection.Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study.Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction follIrinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched AnalysisSafety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosisDecreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas.Pharmacogenetic pathway analysis of irinotecan.Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms.Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer.EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Prognostic factors for gastrectomy in elderly patients with gastric cancerPerioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis.Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials.MicroRNA‑197 reverses the drug resistance of fluorouracil‑induced SGC7901 cells by targeting mitogen‑activated protein kinase 1Txr1: an important factor in oxaliplatin resistance in gastric cancer.Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function.Effects of a human compact anti-ErbB2 antibody on gastric cancer.Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.The prognostic significance of extramural venous invasion detected by multiple-row detector computed tomography in stage III gastric cancer.Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection.Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.Paxillin expression is closely linked to the pathogenesis, progression and prognosis of gastric carcinomas.Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
P2860
Q24296637-97128A93-7421-4F11-8941-72B6FB2BA649Q28278471-C26A19F1-93EC-4251-89D8-46166EF024E3Q28474358-C64A5C58-DAB2-4EF5-AF95-3CD4ED4FBF8FQ28486245-58E1331A-1983-45CD-B3E2-94B771B0BD7BQ33609291-826BADF9-6D33-45D7-A3B6-461C5A8CF687Q33728364-D4F44FFE-EC9F-40AA-998A-50660D7D362BQ33842748-B6BA3D24-9593-4C26-89E1-3010889C4A50Q34105169-E4438E5F-2219-4A68-8B46-0AC440441D3BQ34413771-2F401834-020B-4A97-A656-EC41BFA7EC0FQ34670947-A2989B65-B8DD-4DA4-BA62-61239048A761Q35134424-896E1EC4-3347-4F30-B5FF-42493E6E2CD9Q35713406-2C2CB16F-C3FA-49EB-96C6-904F790DEED3Q35816778-0786B412-8323-42A1-BD87-68614A601091Q36516605-66B58203-CCDC-4BB7-92E8-81668EA8C712Q36611088-100AAE70-A743-4006-8875-0AADB90FFD9DQ36837966-D398230C-30CB-49A9-B785-A83949939409Q36851100-CF55446A-7984-4C0A-83D3-C961B707D67FQ37020109-F3D300C0-0226-4F4B-BDC9-7D6343750A89Q37269223-779D082C-ABBA-4F44-A702-460D9746EE14Q37381224-56FD660E-8049-4EE7-8F01-2E9E5BBEA261Q37457735-1FBDCAB2-8A90-4E74-95CF-87B23EBFD2D2Q37477979-3A6B5794-1352-4F87-815D-F02DB91C8A61Q37552436-B6744EDB-0083-4399-B17A-05EE0E539357Q37694036-553E6C83-2F17-4459-BF7C-44CA5F5B94A3Q37717181-1A2D1467-4D70-4455-9800-12AFBAFD6C87Q38410192-C0BCCF4B-511F-4150-9A61-EE8A87BDE193Q38855825-0F968386-A633-43A9-AAA1-41886D71FE38Q39040996-D8BC6E08-F87F-441A-BF8A-E514275A9E23Q39136321-9BD17E65-7E14-4EF1-96CD-61DA2B7AEF2EQ39183426-9362D26B-899D-4B8E-92C4-372DF410B975Q39185414-D3EB583A-2DF3-4AD8-AE7A-D43185DD4B4BQ39599249-FAB245C9-A4E2-4D51-A732-0AAE064F31AEQ39685742-CC6E44C0-C5DD-44B6-BF75-3DCC57AEC3A5Q39728271-E2DD66E1-D308-4417-B6F6-7C263CCAE9CFQ40695084-A76F7C1A-5AB8-46DC-A87D-30F402AC53BAQ40906898-3C85CCDE-D67C-43BD-A5FC-D8BDCD5DB8C0Q41608289-3C0DE326-6B80-4786-BF74-D2C90CBB57ABQ42095789-2E88AF2C-D96D-4ECD-AE9A-F2ED38440562Q42276365-8D24E128-DB5A-41F8-A15D-5DFFA2E60935Q43096314-2C616ED9-C051-425D-A0A0-C2CDEE300C01
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemotherapy of advanced gastric cancer.
@ast
Chemotherapy of advanced gastric cancer.
@en
type
label
Chemotherapy of advanced gastric cancer.
@ast
Chemotherapy of advanced gastric cancer.
@en
prefLabel
Chemotherapy of advanced gastric cancer.
@ast
Chemotherapy of advanced gastric cancer.
@en
P2093
P1476
Chemotherapy of advanced gastric cancer.
@en
P2093
Fernando Rivera
M Eugenia Vega-Villegas
Marta F López-Brea
P304
P356
10.1016/J.CTRV.2007.01.004
P577
2007-03-21T00:00:00Z